News and Events NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia Jun 21, 2021 NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy Jun 1, 2021 NovaBiotics attending the BIO Digital Meeting, June 2021 May 21, 2021 Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news Mar 30, 2021 Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics Feb 26, 2021 NovaBiotics Attending BIO CEO & Investor Digital Conference Feb 2, 2021 Just when we thought things were getting better….. Dec 31, 2020 CARE CF 1 oral Lynovex clinical trial data published Dec 29, 2020 NovaBiotics in the press Dec 28, 2020 As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation Nov 18, 2020 « Older Entries Next Entries » Categories Press Releases Events In the news Archives 2021 2020
NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia Jun 21, 2021
NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy Jun 1, 2021
As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation Nov 18, 2020
